InnoCare Pharma Limited
INCPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.82B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.82 Billion |
|---|---|
| Enterprise Value | $-1,271,744,549.00 |
| Earnings per Share | $0.36 |
| Beta | 0.39 |
| Outstanding Shares | 1,764,576,252 |
Return
| Return on Equity | 11.83% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 8.62% |
Valuation & Multiples
| P/E Ratio | 19.24 |
|---|---|
| PEG | -4.92 |
| Price to Sales | 1.6 |
| Price to Book Ratio | 0.4 |
| Enterprise Value to Revenue | 5.35 |
| Enterprise Value to EBIT | 18.92 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 27, 2026
EPS Estimate
$-0.04
Consensus analyst estimateRevenue Estimate
$22.98 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$109.16 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About InnoCare Pharma Limited
1,388 employees
CEO: Jisong Cui
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, a...